Overview

Etanercept SFP in RA Patients

Status:
Completed

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Collaborator:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Etanercept